



Bicara Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024

BOSTON, Mass., January 2, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that Ryan Cohlhepp, Pharm.D., president & chief operating officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:30 p.m. Pacific Time.

Additional information about Bicara Therapeutics can be found on the company's website at www.bicara.com.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The Company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara's lead product candidate, BCA101, is a first-in-class EGFR/TGF- β -trap bifunctional antibody in clinical development for multiple tumor types. For more information, please visit www.bicara.com or follow us on [LinkedIn](#) or [X](#).

Contacts:

Investors

Hannah Deresiewicz
Stern Investor Relations, Inc.
Hannah.Deresiewicz@sternir.com

Media

Dan Budwick
1AB
dan@1abmedia.com

###